This week an FDA advisory committee voted to back a legal path for compounding several peptides that today move mostly through the grey market. A recommendation is not a rule, and nothing is final. But it is a good moment to talk about the thing that actually decides whether that path makes anyone safer: who fills the order.
A licensed pharmacy and a "research use only" website can sell you something that looks identical. The label is not the difference. The oversight behind the label is. Here is how to tell them apart.
Look for a real license you can verify yourself
A legitimate Section 503A compounding pharmacy is licensed by a state board of pharmacy, and every state board keeps a public database you can search. The National Association of Boards of Pharmacy maintains a directory that links to each state's verification portal, where you can confirm a pharmacy is currently licensed, holds any compounding permits the state requires, and has no disciplinary actions against it.
If a seller will not give you a pharmacy name and a state license number you can look up, that is your answer. Anonymous is not a paperwork problem. It is the product.
Watch the language on the bottle
Grey-market vials are almost always sold "for research use only" or "not for human consumption." That phrasing is not a wink. It is how a seller opts out of every rule that protects a patient - no prescription, no pharmacist, no verified purity, no recourse if something is wrong. A real pharmacy dispenses against a prescription from a licensed clinician. A research-chemical site sells to anyone with a card.
Ask who made it and who checked it
The present danger in the peptide story has never really been the molecule. It is the unverified vial: the contaminants, wrong doses, and mislabeling that turn up when nobody is accountable for what is inside. A licensed compounder sources from documented suppliers and answers to a regulator. An overseas parcel answers to no one. You can read more on our safety page, and follow where the rule itself stands on the regulatory tracker.
Why Peppies cares which one you use
We will say our bias plainly: Peppies wants a legal, tested pathway to win, because a supervised prescription is how the grey market ends. That is a policy position, not a neutral fact, and you can read the rest of it on our about page.
None of this is medical advice, and none of these peptides is FDA-approved. They have not been evaluated by the FDA, and we make no claim that any peptide is safe or effective. What we are saying is narrower and, we think, harder to argue with: if you are going to get a medicine, get it from someone a regulator can find.
By Peppies.